Key statistics
As of last trade Immatics NV (4A3:DUS) traded at 8.22, -18.21% below its 52-week high of 10.05, set on Dec 05, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.21 |
|---|---|
| High | 8.22 |
| Low | 8.21 |
| Bid | 8.23 |
| Offer | 8.45 |
| Previous close | 8.40 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 121.56m |
| Free float | 89.31m |
| P/E (TTM) | -- |
| Market cap | 1.20bn USD |
| EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 11:31 GMT.
More ▼
Announcements
- Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
- Immatics Announces $125 Million Underwritten Offering
- Immatics Announces Third Quarter 2025 Financial Results and Business Update
- Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
- Immatics Appoints Amie Krause as Chief People Officer
- Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
- Immatics Appoints Venkat Ramanan as Chief Financial Officer
- Immatics Announces Second Quarter 2025 Financial Results and Business Update
- Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
- Immatics Announces First Quarter 2025 Financial Results and Business Update
More ▼
